BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
NCT06704152
Recruiting
The goal of this clinical trial is to test BSB-1001 which is a new type of cellular therapy to treat blood cancers (AML, ALL and MDS). It will evaluate the safety of BSB-1001 and also determine whether it works to prevent relapse of your cancer.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/07/2025
Locations: City of Hope National Medical Center, Duarte, California +4 locations
Conditions: AML, Adult Recurrent, ALL, Recurrent, Adult, MDS
Register for Updates
Growing Little PEAPODS Study
NCT06226051
Recruiting
The goal of this clinical trial is to learn more about how the food and nutrition babies receive while in the Neonatal Intensive Care Unit (NICU) influences their ability to gain weight and fat-free mass, and their future growth and development. Participants will: * have body growth measurements collected using the PEAPOD device * have nutritional information collected, and * be followed for neurodevelopmental outcomes Participants can expect to be in the study for 36 months.
Gender:
ALL
Ages:
Between 22 weeks and 32 weeks
Trial Updated:
08/07/2025
Locations: Meriter Hospital, Inc., Madison, Wisconsin
Conditions: Premature Birth, Premature Infant, Premature, Intrauterine Growth Restriction, Small for Gestational Age at Delivery
Register for Updates
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
NCT06644768
Recruiting
This study will compare Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in First-line NSCLC Without Actionable Genomic Alterations
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: University of California San Diego (Ucsd)-Moores Cancer Center, La Jolla, California +44 locations
Conditions: Non-small Cell Lung Cancer, Lung Cancer
Register for Updates
The Role of 4 Different Consent Approaches on a Pilot Study to Increase Cardiac Rehabilitation Attendance
NCT07123480
Recruiting
Cardiac Rehabilitation is a lifestyle and exercise program for patients with heart disease. Cardiac Rehabilitation is strongly recommended in guidelines, but only 30% of eligible patients attend. New strategies are needed to help more patients attend cardiac rehabilitation. In this study, the investigators will see if using an $50 incentive, case management, text messages, and physical activity coaching combined into a single intervention will help more patients attend cardiac rehabilitation.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Baystate Medical Center, Springfield, Massachusetts
Conditions: Ethics, Cardiac Rehabilitation, Coronary Heart Disease (CHD), Heart Failure, Percutaneous Coronary Intervention (PCI), Aortic Valve Replacement, Myocardial Infarction (MI)
Register for Updates
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
NCT06590857
Recruiting
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Research Facility, Phoenix, Arizona +22 locations
Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
Register for Updates
Dose-Response to Resistance Exercise on Cardiovascular Health
NCT06619444
Recruiting
A large body of evidence indicates numerous health benefits of physical activity, including prevention of cardiovascular disease (CVD), the leading cause of death in the US. This evidence has led to US Physical Activity Guidelines that recommend ≥150 min/week of moderate or ≥75 min/week of vigorous aerobic exercise (AE), plus resistance exercise (RE; such as weight lifting) on ≥2 days/week. To date, current research has mostly focused on AE, and we know a great deal about the dose-response relat... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/07/2025
Locations: Physical Activity Research Center (PARC), Pittsburgh, Pennsylvania
Conditions: Cardiovascular Risk
Register for Updates
A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
NCT07123038
Recruiting
To assess the emergence, type, severity, and potential causality of delayed adverse events following administration of a gene-modified Treg therapeutic.
Gender:
ALL
Ages:
Between 18 years and 71 years
Trial Updated:
08/07/2025
Locations: UCSF Medical Center, San Francisco, California +9 locations
Conditions: Rheumatoid Arthritis (RA), Hidradenitis Suppurativa (HS)
Register for Updates
Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia
NCT06769490
Recruiting
The goal of this all-oral combination is to deliver safe and effective therapy for the largest portion of AML subtypes (NPM1mt, KMT2Ar, NUP98r \~ 40-45%).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia
Register for Updates
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
NCT06598462
Recruiting
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solrikitug in adult participants with eosinophilic esophagitis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/07/2025
Locations: Research Site 1039, Dothan, Alabama +55 locations
Conditions: Eosinophilic Esophagitis (EoE)
Register for Updates
Lung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy.
NCT07125079
Recruiting
Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) is a condition where high levels of inflammation damage the lung. This is a highly morbid condition with no specific pharmacologic therapies. The investigators posit that ARDS is caused due to an exaggerated activation of immune cells and that blockade of this activation may reduce lung damage/injury and help in ARDS management and possibly recovery. To test this hypothesis, the investigators propose to generate an in vitro i... Read More
Gender:
ALL
Ages:
Between 21 years and 90 years
Trial Updated:
08/07/2025
Locations: Hospital Of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: ARDS (Acute Respiratory Distress Syndrome)
Register for Updates
Mifepristone vs Misoprostol
NCT06502158
Recruiting
The Investigator team hypothesizes that in a randomized trial comparing mifepristone-alone or misoprostol-alone for cervical preparation for procedural abortions at 12 to 16 weeks in hospital-based care, the proportion of patients who achieve successful cervical dilation will be different between the study groups.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
08/07/2025
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Cervical Preparation
Register for Updates
AAV Gene Therapy Clinical Study in Adult Classic PKU (PHEdom)
NCT06332807
Recruiting
This is a Phase 1/2, open-label, multiple-center, dose escalation and cohort expansion study to evaluate the safety and efficacy of NGGT002 in adult subjects with classic Phenylketonuria (PKU). NGGT002 is an rAAV8 based vector carrying a functional copy of the human PAH gene. Participants will receive a single administration of NGGT002 and will be followed for safety and efficacy for 5 years.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/07/2025
Locations: University of Minnesota, Minneapolis, Minnesota +3 locations
Conditions: Phenylketonurias
Register for Updates